Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $2.6 million.

  • Atara Biotherapeutics' Accumulated Expenses fell 6833.35% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 6833.35%. This contributed to the annual value of $6.6 million for FY2024, which is 6533.38% down from last year.
  • Atara Biotherapeutics' Accumulated Expenses amounted to $2.6 million in Q3 2025, which was down 6833.35% from $4.8 million recorded in Q2 2025.
  • In the past 5 years, Atara Biotherapeutics' Accumulated Expenses registered a high of $19.0 million during Q4 2023, and its lowest value of $2.6 million during Q3 2025.
  • Moreover, its 4-year median value for Accumulated Expenses was $12.6 million (2023), whereas its average is $12.2 million.
  • In the last 5 years, Atara Biotherapeutics' Accumulated Expenses skyrocketed by 10422.98% in 2024 and then crashed by 6833.35% in 2025.
  • Atara Biotherapeutics' Accumulated Expenses (Quarter) stood at $17.7 million in 2022, then grew by 7.63% to $19.0 million in 2023, then tumbled by 65.33% to $6.6 million in 2024, then tumbled by 61.27% to $2.6 million in 2025.
  • Its Accumulated Expenses was $2.6 million in Q3 2025, compared to $4.8 million in Q2 2025 and $9.5 million in Q1 2025.